OCUMENSION THERAPEUTICS
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
OCUMENSION THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
+86 (021)-61493800
Email Addresses:
[email protected]
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Euro JsDelivr GStatic Google Static Content Pound Sterling IIS 10 Japanese Yen
Current Employees Featured
Stock Details
Investors List
General Atlantic
General Atlantic investment in Series B - Ocumension Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-04-14 | Alimera Sciences | Ocumension Therapeutics investment in Post-IPO Equity - Alimera Sciences | 20 M USD |
| 2021-01-03 | EyePoint Pharmaceuticals | Ocumension Therapeutics investment in Post-IPO Equity - EyePoint Pharmaceuticals | 15.7 M USD |
More informations about "Ocumension Therapeutics"
欧康维视,OcuMension
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic …See details»
欧康维视,OcuMension
Shanghai, China – On August 12, 2024, Ocumension Therapeutics (“OcuMension”) announced an agreement with Alcon Inc. (“Alcon”, and collectively with OcuMension, the “Parties”) where …See details»
Ocumension Therapeutics - PitchBook
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in …See details»
EyePoint Pharmaceuticals and OcuMension Therapeutics
Jun 21, 2022 On 10 July 2020, OcuMension Therapeutics was listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 01477). For more information on …See details»
Ocumension Therapeutics - Drug pipelines, Patents, Clinical trials ...
Explore Ocumension Therapeutics with its drug pipeline, therapeutic area, technology platform, 13 clinical trials, 77 news, Disease Domain:Endocrinology and Metabolic Disease, Immune …See details»
Ocumension Therapeutics - Funding, Financials, Valuation
Ocumension Therapeutics is registered under the ticker HKG:1477 . Ocumension Therapeutics is funded by 3 investors. ... How much funding has this organization raised over time? Show . …See details»
Ocumension Therapeutics, 1477:HKG profile - FT.com - Financial …
6 days ago Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products …See details»
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign …
About Ocumension Therapeutics Ocumension is a China-based company with a mission of being a pioneer in Ophthalmology. It is controlled by 6 Dimensions Capital, a global investment firm …See details»
Ocumension Therapeutics Company Profile - Craft
Aug 16, 2024 Ocumension Therapeutics ¥246.37 m in annual revenue in FY 2023. See insights on Ocumension Therapeutics including office locations, competitors, revenue, financials, …See details»
Ocumension Therapeutics Announces 2022 Annual …
Mar 30, 2023 Youshiying (OT-401), Company’s Core Product, Commercialized ahead of Schedule Speed up the Launch of New Products Ocumension Therapeutics (Ocumension or the Company, together with its subsidiaries, …See details»
EyePoint Pharmaceuticals and OcuMension Therapeutics …
Jun 21, 2022 WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to …See details»
Ocumension Therapeutics, 1477:HKG summary - FT.com
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include …See details»
Ocumension Therapeutics Announces Phase II Clinical Trial of OT …
Mar 14, 2024 Ocumension Therapeutics announced that, the phase II clinical trial of OT-202 (tyrosine kinase inhibitor), a first-in-class new drug self-developed by the Company for the …See details»
Ocumension (01477.HK) Demonstrates Strong Operational …
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its …See details»
OcuMension acquires rights to Alcon eye drops in exchange for a …
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with …See details»
Ocumension Therapeutics Announces CDE Approval Received for …
Jul 13, 2021 Ocumension Therapeutics announced that OT-101 (0.01% atropine sulfate eye drop), a self-developed new drug to treat the progression of myopia in children, was approved …See details»
Ocumension Therapeutics ESG Risk Rating - Sustainalytics
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total …See details»
Ocumension Therapeutics Announces Phase III Clinical Trial of OT …
Apr 15, 2024 The board of directors of Ocumension Therapeutics announced that, OT-502 (DEXYCU, dexamethasone implant), a new drug for the treatment of postoperative …See details»
Ocumension Therapeutics Announces 2021 Interim Results - PR …
HONG KONG, Aug. 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company, Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the …See details»
PTC Therapeutics Enters into a Global License and Collaboration ...
6 hours ago About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that …See details»